Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $175,585.68 in Stock

Posted by George Bondi on Apr 18th, 2026

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $27.66, for a total value of $175,585.68. Following the completion of the transaction, the insider directly owned 69,792 shares in the company, valued at $1,930,446.72. This represents a 8.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total value of $373,099.32.
On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total value of $59,414.60.
On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total value of $173,744.76.
On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total value of $369,163.08.
On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total value of $58,269.64.
On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total value of $11,505.03.
On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total value of $184,057.51.
On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total value of $385,669.20.
On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total value of $65,585.91.
On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total value of $13,353.60.

Mineralys Therapeutics Trading Up 0.1%

Shares of NASDAQ MLYS opened at $30.58 on Friday. Mineralys Therapeutics, Inc. has a one year low of $12.59 and a one year high of $47.65. The firm has a market capitalization of $2.52 billion, a PE ratio of -12.90 and a beta of 0.69. The business has a 50-day moving average price of $27.32 and a two-hundred day moving average price of $34.27.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. Research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Wall Street Analysts Forecast Growth

MLYS has been the subject of a number of research reports. Stifel Nicolaus raised their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Wall Street Zen upgraded Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Thursday, January 22nd. Bank of America lifted their price target on Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a report on Friday, March 13th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.14.

View Our Latest Stock Report on MLYS

Institutional Investors Weigh In On Mineralys Therapeutics

Institutional investors have recently made changes to their positions in the company. Navalign LLC acquired a new stake in shares of Mineralys Therapeutics during the 4th quarter valued at about $33,000. Smartleaf Asset Management LLC lifted its holdings in shares of Mineralys Therapeutics by 198.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after buying an additional 676 shares during the last quarter. Royal Bank of Canada lifted its holdings in shares of Mineralys Therapeutics by 262.3% during the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after buying an additional 1,107 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Mineralys Therapeutics by 1,845.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock valued at $76,000 after buying an additional 1,993 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company’s stock valued at $124,000 after buying an additional 3,241 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

(Get Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.